ABBOTT LABORATORIES
ABT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ABT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABT
Abbott Laboratories is a diversified healthcare company that develops and sells medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals, with a focus on innovation and global market leadership.
Key risk: Foreign exchange exposure
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$195.90B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Tracking 24 clinical trials for ABBOTT LABORATORIES.
Abbott Laboratories is a diversified healthcare company that develops and sells medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals, with a focus on innovation and global market leadership.
- Abbott's revenues are derived from medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals, with international markets comprising 61% of consolidated net sales [sec_mda · as of 2026-02-20].
- As of March 31, 2026, Abbott reported cash & equivalents of $6,803.0M, total revenue of $11,164.0M, and net income of $1,077.0M [sec].
- Abbott returned $5 billion to shareholders in 2025 and announced a 6.8% dividend increase for 2026, marking the 54th consecutive year of dividend increases [sec · filed 2026-03-13].
- The company is focusing on innovation across its segments, including next-generation diagnostics systems, nutritional platforms, and expansion of its established pharmaceuticals portfolio in emerging markets [sec_mda · as of 2026-02-20].
- Abbott's operating margin profile decreased from 23.8% in 2023 to 23.3% in 2025, reflecting increased business costs and unfavorable foreign exchange [sec_mda · as of 2026-02-20].
What works
- Abbott has a diversified business model with leadership positions in large and fast-growing healthcare markets, which supports consistent top-tier returns [sec · filed 2026-03-13].
- The company has a robust innovation pipeline with a steady cadence of important product approvals expected to contribute to growth in coming years [sec · filed 2026-03-13].
- Abbott continues to invest in future growth by increasing manufacturing scale and capabilities across several important products, including a larger U.S. footprint [sec · filed 2026-03-13].
What to weigh
- Operating margin profile decreased from 23.8% in 2023 to 23.3% in 2025, reflecting increased business costs and unfavorable foreign exchange [sec_mda · as of 2026-02-20].
- Sales growth in the established pharmaceuticals segment is impacted by price controls, competition, and rebates, which affect net selling prices [sec_mda · as of 2026-02-20].
- The company faces foreign exchange headwinds, as international markets comprise 61% of consolidated net sales [sec_mda · as of 2026-02-20].
From the filings
Quoted directly from source documents.
Abbott's diversified business model drives consistent returns
“These consistent top-tier returns are driven by strong execution, an effective governance structure, and the strength of our diversified business model with leadership positions in some of the largest and fastest-growing markets in healthcare and innovative product portfolios across our businesses.”
SEC filings · March 13, 2026
Abbott has a robust innovation pipeline
“Robust innovation pipeline•Steady cadence of important product approvals across our businesses that will be significant contributors to growth in the coming years.”
SEC filings · March 13, 2026
Abbott returned $5 billion to shareholders in 2025
“Returned $5 billion to shareholders in 2025 and announced a 6.8% increase to our dividend for 2026, marking our 54th consecutive year of dividend increases.”
SEC filings · March 13, 2026
International markets comprise 61% of net sales
“Sales in international markets comprise 61 percent of consolidated net sa”
SEC MD&A · February 20, 2026
Risks & what to watch (3)›
Key risks
- Foreign exchange exposure — International markets comprise 61% of net sales, making Abbott vulnerable to unfavorable foreign currency impacts on revenue and margins [sec_mda · as of 2026-02-20].
- Operating margin pressure — Operating margin decreased from 23.8% in 2023 to 23.3% in 2025 due to increased business costs and unfavorable foreign exchange [sec_mda · as of 2026-02-20].
- Price controls and competition — Price controls, competition, and rebates significantly impact net selling prices of products, particularly in established pharmaceuticals [sec_mda · as of 2026-02-20].
What to watch
- Monitor the impact of foreign exchange on revenue and margins, given that 61% of sales are international [sec_mda · as of 2026-02-20].
- Track the launch and commercial performance of new products from the innovation pipeline, which are expected to contribute to growth [sec · filed 2026-03-13].
- Watch for updates on manufacturing expansion and capital projects in the U.S. [sec · filed 2026-03-13].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run ABBOTT LABORATORIES through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ABBOTT LABORATORIES facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 1.12 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 1 sell (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3,070
Total value held
$141.93B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 225,899,866 | $23.19B |
| blackrock, inc. | 145,793,958 | $14.97B |
| state street corp | 79,575,468 | $8.17B |
| vanguard portfolio management llc | 47,944,891 | $4.92B |
| charles schwab investment management inc | 45,500,055 | $4.67B |
| geode capital management, llc | 39,148,795 | $4.00B |
| morgan stanley | 30,101,596 | $3.09B |
| wellington management group llp | 27,070,518 | $2.78B |
| jpmorgan chase & co | 26,767,099 | $2.73B |
| franklin resources inc | 20,022,905 | $2.06B |
Showing top 10 of 3,070 institutional holders of ABBOTT LABORATORIES. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.5%
- Days to cover
- 1.8
- Shares short
- 22,536,486
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABT short interestGovernance
Frequently asked questions
What is the AI investment thesis for ABBOTT LABORATORIES?
Abbott Laboratories is a diversified healthcare company that develops and sells medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals, with a focus on innovation and global market leadership.
Who is the CEO of ABBOTT LABORATORIES?
Mr. Robert B. Ford is the chief executive officer of ABBOTT LABORATORIES (ABT).
Where is ABBOTT LABORATORIES headquartered?
ABBOTT LABORATORIES (ABT) is headquartered in Abbott Park, IL, United States.
What therapeutic areas does ABBOTT LABORATORIES focus on?
ABBOTT LABORATORIES develops therapies across Oncology, Rare Disease, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Gastroenterology, Endocrinology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.